Transgenomic EGFR CLIA Test
Transgenomic has launched its new CLIA laboratory-based test for EGFR mutation detection in cancer patients using proprietary MX-ICP technology with any sample type.
The test is for EGFR exon 20 T790M mutations that affect the utility of tyrosine kinase inhibitor drugs for non-small cell lung cancer and EGFR exon 12 S492R mutations that signify resistance to the widely-prescribed drug cetuximab in coloretal cancer patients.
The test can use tissue, plasma, fine needle aspiration, bronchoscopy, cytology, and other bodily fluid samples. Actionable results will be available in seven to 10 working days, Transgenomic said.